Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16039620 | 1.00 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2LMNAMAPTCRHBP | |
| SCHEMBL16039622 | 1.00 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2LMNAMAPTCRHBP | |
| SCHEMBL25293532 | 0.87 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2LMNAMAPTCRHBP | |
| SCHEMBL9466546 | 0.81 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNAMAPTCRHBP | |
| SCHEMBL16039841 | 0.77 | CA1 (0.44) | CA1CA2CA7CA9 | |
| SCHEMBL8169563 | 0.77 | ALDH1A1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL8169565 | 0.77 | ALDH1A1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL8169561 | 0.77 | ALDH1A1 (0.44) | ALDH1A1LMNA | |
| SCHEMBL21329586 | 0.77 | MEN1 (0.39) | ALDH1A1LMNAGAACA1CA2 | |
| SCHEMBL21330105 | 0.77 | MEN1 (0.39) | ALDH1A1LMNAGAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169256-B2 | Artificial nucleic acids | ELITECHGROUP B.V. (NL) | 2015-10-27 | — | — | US | disclosed |
| US-20140275508-A1 | ARTIFICIAL NUCLEIC ACIDS | ELITECH HOLDING B.V. (NL) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275508-A1 | ARTIFICIAL NUCLEIC ACIDS | NSUN2, POLRMT, NSUN3 | ALDH1A1 1797/4885SMN1; SMN2 308/4885LMNA 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.